Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
SUM1315MO2 | Pictilisib | pan PI3K | PI3K/mTOR | 0.51112 | 0.1300 | 0.3707 | 0.0433 | 0.4384 | 0.96851 | 0.98439 |
SUM1315MO2 | Ceritinib | ALK | RTK | 0.6688 | -0.7650 | 0.4135 | 0.0975 | 1.0318 | 1.9396 | 0.99439 |
SUM1315MO2 | Neratinib | EGFR/HER2 | RTK | 0.092366 | 0.1140 | 0.3661 | 0.0353 | 0.9382 | 0.073122 | 0.99266 |
SUM1315MO2 | Tivantinib | MET | RTK | 0.36967 | -0.4300 | 0.4751 | 0.1718 | 2.1700 | 0.49553 | 0.9978 |
SUM1315MO2 | Cediranib | VEGFR/cKIT | RTK | 1.4839 | -0.2276 | 0.2430 | 0.0500 | 0.7936 | 5.924 | 0.99038 |
SUM1315MO2 | Cabozantinib | VEGFR2/MET | RTK | 4.5316 | 0.1095 | 0.1089 | 0.0163 | 1.1058 | 12.2361 | 0.99069 |
SUM159PT | Abemaciclib | CDK4/6 | Cell cycle | 0.28398 | -0.4677 | 0.4585 | 0.1015 | 0.4799 | 2.802 | 0.95259 |
SUM159PT | Palbociclib | CDK4/6 | Cell cycle | 1.1058 | 0.3876 | 0.1990 | -0.0006 | 0.6326 | 0.40763 | 0.99661 |
SUM159PT | AZD7762 | CHK1/2 | Cell cycle | 0.81589 | -0.1124 | 0.2697 | 0.0926 | 1.5031 | 0.93462 | 0.99443 |
SUM159PT | Volasertib | PLK | Cell cycle | 0.024832 | 0.0468 | 0.3873 | 0.1208 | 3.5660 | 0.024055 | 0.99966 |
SUM159PT | Dinaciclib | pan CDK | Cell cycle | 0.016967 | -0.0646 | 0.4536 | 0.1030 | 5.0000 | 0.017277 | 0.99948 |
SUM159PT | Cisplatin | Chemo | Chemotherapy | 5.2539 | 0.1742 | 0.1149 | 0.0416 | 1.1412 | 13.758 | 0.99717 |
SUM159PT | Doxorubicin | Chemo | Chemotherapy | 0.019121 | -0.2740 | 0.6068 | 0.2965 | 1.5857 | 0.022541 | 0.98806 |
SUM159PT | Taxol | Chemo | Chemotherapy | 0.0047473 | -0.1485 | 0.6380 | 0.2976 | 2.2238 | 0.0052544 | 0.99906 |
SUM159PT | Topotecan | Topo I | Chemotherapy | 0.019593 | -0.3284 | 0.7927 | 0.3329 | 1.4860 | 0.025267 | 0.97848 |
SUM159PT | Etoposide | Topo II | Chemotherapy | 0.41904 | -0.1489 | 0.3736 | 0.1389 | 1.7468 | 0.47824 | 0.99862 |
SUM159PT | Dasatinib | BCR/ABL | MAPK/nRTK | Inf | 0.5642 | 0.1850 | 0.0047 | 1.3689 | 0.14044 | 0.98104 |
SUM159PT | Trametinib | MEK | MAPK/nRTK | 0.0055877 | 0.2792 | 0.4613 | 0.0039 | 0.9923 | 0.0023029 | 0.99862 |
SUM159PT | Saracatinib | SRC | MAPK/nRTK | 13.9057 | 0.5624 | 0.0724 | -0.0011 | 0.9804 | 8.3037 | 0.99931 |
SUM159PT | ABT-737 | Bcl2/XL | Misc | 14.892 | 0.6822 | 0.0239 | 0.0074 | 1.9362 | 14.743 | 0.99356 |
SUM159PT | Vorinostat | HDAC | Misc | 1.9985 | 0.1195 | 0.1810 | 0.0216 | 1.3229 | 1.9352 | 0.99956 |
SUM159PT | Luminespib | HSP90 | Misc | 0.0063084 | -0.0476 | 0.5743 | 0.2156 | 4.5596 | 0.0064127 | 0.9997 |
SUM159PT | A-1210477 | Mcl-1 | Misc | 15.1726 | 0.7796 | 0.0000 | 0.0026 | 4.9964 | 11.2086 | 0.95671 |
SUM159PT | Olaparib | PARP | Misc | 18.3192 | 0.7244 | 0.0350 | 0.0011 | 1.2272 | 44.7404 | 0.98618 |
SUM159PT | Bleomycin | Radiation | Misc | 0.28119 | -0.0577 | 0.4191 | 0.1680 | 0.7700 | 0.38984 | 0.99881 |